RecruitingPhase 2NCT07285590
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Eva Giné SocaHospital Clinic of Barcelona
- Intervention
- Pirtobrutinib and rituximab(drug)
- Enrollment
- 50 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (16)
- Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Lisbon District, Portugal
- Unidade Local De Saude De Santa Maria E.P.E., Lisbon, Lisbon District, Portugal
- INSTITUT CATALÀ D'ONCOLOGIA (ICO). Hospital Germans Trias I Pujol., Badalona, Barcelona, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Barcelona, Spain
- Hospital Clinic de Barcelona, Barcelona, Barcelona, Spain
- Institut Català d'oncologia de L'Hospitalet (ICO-L'Hospitalet), L'Hospitalet de Llobregat, Barcelona, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
- Clínica Universidad Navarra, Madrid, Madrid, Spain
- Hospital Ramon y Cajal, Madrid, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
- Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
- Hospital Costa del Sol, Marbella, Málaga, Spain
- Clínica Universidad Navarra, Pamplona, Pamplona, Spain
- Hospital Universitario de Salamanca, Salamanca, Salamanca, Spain
- Hospital Clínico de Valencia, Valencia, Valencia, Spain
- +1 more locations on ClinicalTrials.gov
Collaborators
Evidenze CRO · Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07285590 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE1NCT07284927Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGPHASE1NCT07283796A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06838832Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHLChinese PLA General Hospital
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan